Topic
340B
257 published works
Health Law Diagnosis
Supreme Court Decides in Favor of 340B Hospitals Regarding Medicare Reimbursement Methodology
By Conor Duffy, Robinson+Cole's Health Law Group
On June 15, 2022, the U.S. Supreme Court unanimously ruled in favor of “340B” hospitals in a notable statutory interpretation case concerning how the federal Medicare program reimburses hospitals for…
To Be or Not to 340B Blog
Federal Spending Bill Offers Re-Enrollment Path for Some Hospitals
By Michael French, Brenda Maloney Shafer, Richard Davis
UPDATED on 3/22/2022 In a move welcomed by the growing number of hospitals forced out of the 340B Program due to falling disproportionate share hospital (DSH) adjustment percentages, Congress has…
Health Law Diagnosis
Delaware District Court Determines that HRSA Enforcement Letter Targeting 340B Program Restrictions Violates the APA
By Robinson+Cole's Health Law Group
A federal court in Delaware recently determined that the Health Resources and Services Administration (HRSA) – the federal agency responsible for administering the 340B drug pricing program – did not…
Medicaid and the Law
Supreme Court Hears Arguments on 340B Outpatient Payment Cuts—and Discusses ‘Chevron Deference’
Over the summer, my colleague Tom Barker discussed how the Supreme Court was planning to hear several health care cases during the October 2021 term. Last week, the Court heard…
Medicaid and the Law
District Courts Issue Key Decisions in 340B Contract Pharmacy Cases
Over the last two weeks we have seen a flurry of activity from U.S. District Courts across the country in the ongoing contract pharmacy disputes between pharmaceutical manufacturers and HRSA,…
Medicaid and the Law
Supreme Court Will Hear Several Health Care Cases in 2022 Term
Recently, my colleague Regina DeSantis told you about the ongoing saga involving disputes between 340B contract pharmacies and pharmaceutical manufacturers. We often write about the 340B program on our blog…
Healthcare Law Blog
340B Drug Pricing Discount Program Update: HRSA Now Demands That Drug Manufacturers Provide 340B Discounts To Contract Pharmacies Amid Ongoing Litigation
By Erica Kraus, Stephanie Awanyai-Ufondu
Now approaching a year-long battle, drug manufacturers and 340B covered entities, which include hospitals and community health centers, participating in the 340B Drug Pricing Discount Program (“340B Participants”) continue to…
Medicaid and the Law
Summer Reruns: ‘340B Contract Pharmacy Saga’ Back in the Spotlight as OGC Withdraws Advisory Opinion
Like the Brood X cicadas emerging from their 17-year chthonic slumber, summer 2021 saw the reemergence of something else set to dominate headlines: 340B contract pharmacies. Given the link between…
Health Care Law Today
Court Sides with Drug Manufacturers in Ongoing 340B Litigation
By Anil Shankar, Samantha Robbins Jamali
Over the last year, covered entities participating in the 340B Drug Pricing Program (340B Program) have anxiously monitored a flurry of litigation that could determine the scope of the 340B…
Healthcare Law Insights
340B Update: HRSA Notifies Six Manufacturers that They are in Violation of the 340B Statute
By Tiffany A. Hetland, Pete Enko
Since mid-2020, many pharmaceutical manufacturers have introduced policies that scope their offering of 340B pricing, including limiting contract pharmacy arrangements and requiring covered entities to submit claims data. These policies…